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Summary We have carried out experiments to determine the response of tumours and normal tissues in the
C3H mouse to the combination of lipophilic nitroimidazoles and CCNU, cyclophosphamide or melphalan.
The nitroimidazoles studied were Ro 07-1902 (1902) and benznidazole (Ro 07-1051, BENZO). Maximum
enhancement of CCNU response in the KHT sarcoma by 2.5mmolkg-1 1902 or 0.3mmolkg-1 BENZO
occurred at low doses of CCNU where dose modifying factors (DMF) of 2.5-3.0 and 1.5-2.0 respectively
were found. The DMFs for depression of white cell count at day 3 were 1.6 and 1.2 respectively whilst the
DMFs for LD30/30 were 1.5 and 1.3. There appears, therefore, to be a therapeutic gain at low doses of CCNU
of about the same magnitude as produced by 2.5mmolkg-I misonidazole. The production of this gain at
relatively low doses of BENZO is of possible clinical significance. Some sensitization of the KHT tumour to
CCNU by 0.3mmolkg-1 BENZO was maintained even with an interval of 25h between BENZO and CCNU
injection. A multiple injection regime of BENZO administration designed to maintain plasma concentrations
for prolonged periods was, however, no more effective than a single dose.
The response of the RIF-l sarcoma to cyclophosphamide was not enhanced by the lipophilic sensitizers at
the doses previously stated. Considerable enhancement of tumour response to melphalan (DMF 2.0) was
produced by both lipophilic sensitizers. Enhancement of acute LD50 was similar in magnitude but no large
enhancement by BENZO of melphalan induced white blood cell depression was observed. The evidence
regarding the therapeutic potential of this combination is, therefore, equivocal.
It has been shown that by adding the
radiosensitizer, misonidazole (MISO), to the
nitrosourea, CCNU, an increase in the response of
experimental mouse tumours can be achieved
without a concommitant increase in normal tissue
toxicity (Siemann, 1981, 1982; Twentyman, 1981;
Twentyman & Workman, 1982; Hirst et al., 1982).
Following these observations, we examined the
ability to enhance the effect of CCNU against the
KHT sarcoma of a series of neutral 2-
nitroimidazoles, similar in electron-affinity but
varying in octanol-water partition coefficient (PC)
over 4 orders of magnitude (Workman &
Twentyman, 1982). Analogues more hydrophilic
than MISO were inactive, as were those with very
high PCs (i.e. >20, MISO=0.43). Those with PCs
between 0.43 and 20 were usually more active than
MISO, and two of the most effective agents were
benznidazole (Ro 07-1051, BENZO) and Ro 07-1902
(1902). Dose-response curves for these agents
showed that benznidazole was effective down to very
low doses (0.05-0.3mmolkg-1).
In this paper we examine in more detail the
effects of BENZO and 1902 in combination with
CCNU on the response of the KHT tumour
and of normal tissues in the mouse. We also report
upon experiments combining these agents with
cyclophosphamide (CTX) and mephalan (MEL) in
the RIF-I mouse sarcoma.
Materials and methods
Mice and tumours
The mice used in these studies were inbred C3H/He
supplied by OLAC. Females were used in most
experiments but males were used occasionally. Mice
entered experiments at age 12-16 weeks and
weighed 20-28 g.
Tumours used were the KHT and RIF-I
sarcomas, both of which originated in C3H/Km
mice at Stanford University, California, and which
have been previously described (Kallman et al.,
1967; Twentyman et al., 1980). The methods used
for tumour cell inoculation into the gastrocnemius
muscle of the hind limb and subsequent
measurement of tumour growth, including
conversion of leg measurement to tumour weight,
have also been described (Twentyman et al., 1979).
The endpoint of growth delay was calculated from
the time taken for each tumour to reach 4 times its
initial treatment volume. Tumours were treated in
the size range 300-600mm3.
Nine to 12 mice were used in each treatment
group.
White-cell counts
Blood samples were taken from non-anaesthetised
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mice by cutting a few mm from the end of the tail
with a scalpel. A capillary pipette was then used to
draw up 0.015ml of blood, which was diluted in
20ml of "Isoton" (Coulter Electronics Ltd.). Six
drops of "Zapoglobin" were added to lyse the red
cells, and counts were made on an electronic
particle counter (Coulter Electronics-model ZBI).
Each group contained 5 mice.
Drugs
MISO, BENZO and 1902 were supplied by Roche
(Welwyn). In most experiments, the nitroimidazoles
were injected 30min before the cytotoxic drug. MISO
and 1902 were dissolved in Hanks' balanced salt
solution (HBSS) and injected i.p. in 0.04ml g 1 body
weight. For single and priming doses BENZO was
suspended in 50% v/v polyethylene glycol (MW
400) in HBSS and injected i.p. in 0.005-
0.01 mlg-1; for "top-up" doses in multi-dose
experiments it was dissolved in a mixture of
polyethylene glycol (65%) and propylene glycol
(35%), and then diluted 1:10 with warm HBSS
immediately before i.p. injection in 0.01 ml g-1.
Cytotoxic drugs were obtained, prepared and
administered as shown in Table I. Appropriate
vehicle controls were included in all experiments.
BENZO concentrations in plasma and tumours
were determined by HPLC using a similar method
to that for MISO (Workman et al., 1978) except
that the mobile phase was 60% methanol/water.
Results
Tumour response to CCNU
We have previously shown that, in terms of
enhancement of CCNU effect against the KHT
tumour, 1902 is the most effective sensitizer at a
dose of 2.5mmolkg-1, but that BENZO is better
able to retain its effectiveness at low doses
(Workman & Twentyman, 1982). For further
investigation, therefore, we have largely
concentrated on doses of 2.5mmolkg-1 1902 and
0.3mmolkg 1 BENZO.
Dose-response data for CCNU alone or in
combination with these sensitizer regimes are shown
in Figure 1. The data at 10mgkg1 CCNU in this
and a similar repeat experiment confirm those of
our previous study showing that 2.5mmolkg-1 1902
and 0.3mmolkg-1 BENZO both produce
considerable enhancement of response. With 1902,
the response to 10mgkg-1 CCNU becomes
equivalent to that produced by 25-30mgkg-1 of
CCNU alone (i.e. dose modifying factor = 2.5-3.0),
and with BENZO the response to 10mgkg- is
almost equal to that produced by 20mgkg-1 of
CCNU alone (i.e. dose modifying factor=2.0). This
factor is at the high end of the range found in
repeat experiments with this combination. Most
experiments gave values in the range 1.5-2.0. At
higher doses of CCNU, however, the curves tend to
converge with a consequent progressive reduction in
dose-modifying factors.
Table I Cytotoxic drugs studied
Administered
volume*
Drug Supplier Preparation (mlg-1)
Cyclophosphamide Ward Dissolved in 0.005-0.02
(CTX) Blenkinsopp Ltd. HBSS
Melphalan Chester Beatty Dissolved in acidified 0.01
(MEL) Research Institute ethanol. Diluted 1:10 in
HBSS
1-(2-chlorethyl) U.S. National (a) Dissolved in absolute 0.005-0.05
-3-cyclohexyl- Cancer Institute ethanol. Diluted 1:20 in
1-nitrosourea 0.5% carboxymethyl
(CCNU) cellulose/HBSS
(b) Dissolved in 50:50 mixture 0.01
ofethanol/Cremphore (Sigma)
and diluted 1:5 (v/v) in HBSS
*All drugs administered by the intraperitoneal route.
For CCNU, vehicle (a) was used in all experiments, except the two multi-BENZO
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Figure 1 Growth delay in the KHT sarcoma
produced by varying doses of CCNU. (0) CCNU
alone; (O) BENZO (0.3mmolkg-') given 30min before
CCNU; (0) 1902 (2.5mmolkg-1) given 30min before
CCNU. Points indicate geometric means for groups of
9-12 mice. Error bars show +2s.e.
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Timing ofBENZO administration
In most of our earlier studies, sensitizers were
administered 30min before CCNU. BENZO,
however, has a relatively long in vivo half-life in
mice (Workman et al., in preparation), and we
therefore investigated whether a longer interval
would produce greater enhancement of CCNU. The
results of an experiment using different timing
intervals between BENZO (0.3 and 2.5mmolkg-1)
and CCNU (10mgkg-1) are shown in Figure 2. At
0.3mmolkg-1 BENZO, the enhancement appears to
be similar for sensitizer adminstration between 8h
before and 1 h after CCNU. The effect is lost,
however, if BENZO is not given until 4h after
CCNU. At the higher dose of BENZO, similar
enhancement is seen for administration 8 h or
30min before CCNU. These conclusions were
confirmed in a repeat experiment in which we were
also able to show significant enhancement of
CCNU (0mgkg-1) by0.3mmolkg-1 BENZO given
28 or 18h previously. The growth delays (±2 s.e.)
were CCNU (l0mgkg-1) alone=3.7 (3.0-4.4) days;
CCNU (10 mg kg-1)
, alone
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Figure 2 Growth delay in the KHT sarcoma produced by CCNU in combination with BENZO. (0) CCNU
10mgkg-I alone; (l) CCNU 20mgkg-1 alone; (@) CCNU 10mgkg- given at different times with respect to
BENZO (0.3 mmolkg-1); (A) CCNU 10mg/kg given at different times with respect to BENZO (2.5 mmolkg-1).
Points indicate geometric means for groups of 9-12 mice. Error bars show + 2 s.e.
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CCNU (20mgkg 1) alone=10.1 (9.4-10.8)
days; BENZO (0.3mmolkg)- 128 h-CCNU
(10mgkg-1)=6.0 (5.3-6.8) days; BENZO
(0.3mmolkg-1)18h-CCNU (10mgkg-1)=6.2
(5.0-7.6) days.
Prolonged exposure to BENZO
In order to investigate whether a prolonged
exposure to BENZO gives more sensitization to
CCNU than does a single administration, 2
experiments using a multiple injection regime were
carried out. In the first of these experiments a
priming dose of 0.23mmolkg-1 BENZO was
followed by 15 further injections of0.058mmolkg'-I
at hourly intervals, with the objective of
maintaining the plasma level at around 30pgml-1
(0.12mM). CCNU was administered either at the
beginning, half-way through, or at the end of the
16h regime of BENZO injections. The plasma
BENZO rose to a peak of 45pgml 1 at 4h, but
subsequently fell and remained within the range 30-
40pgml-1 from 8-16h. It may be seen from Figure
3, that the sensitization to CCNU produced by
BENZO is independent of the relative time of
administration. The growth delay produced by
12mgkg 1 CCNU in mice receiving multiple
BENZO was similar to that produced by
18mgkg1 CCNU in mice receiving vehicle. In the
second experiment (Figure 4) we compared the
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Figure 4(a) Growth delay in the KHT sarcoma
produced by CCNU in combination with either single
administration of BENZO or a 16h regime of multiple
_- _ - _ _ {BENZO administration. A, CCNU 1 h after BENZO
vehicle; , CCNU 1h after BENZO (0.3mmolkg-1);
*, CCNU lh after BENZO (1.Ommolkg-1); 0,
CCNU at midpoint of 16h multi BENZO vehicle
regime; 0, CCNU at midpoint of 16h multi BENZO
regime. (b) Plasma and tumour levels of BENZO
during the 16h schedule of multiple administration 0,
12 16 20 plasma; 0, tumour.
Figure 3 Growth delay in the KHT sarcoma
produced by CCNU administered at different times
with respect to a 16h regime of multiple BENZO
injections (or multiple vehicle). Points at 0 time
indicate CCNU administration immediately before
first BENZO injection. Points at 8h and 16h indicate
CCNU administration immediately before 8h and 16h
BENZO injections respectively. E1, multiple vehicle
alone; *, multiple BENZO alone; 0, multiple
vehicle+CCNU 12mgkg 1; A, multiple
vehicle+CCNU 18mgkg-1; O, multiple
vehicle+CCNU 24mgkg-1; , multiple
BENZO+CCNU 12mgkg-1; A, multiple
BENZO+CCNU 18mgkg-1.
effect of the multiple BENZO regime with that of a
single injection. All CCNU administrations were at
the 8h point of the 16h multiple BENZO regime.
Furthermore, following the initial dose of
0.23mmolkg-1 of BENZO, a 2h gap was left
before the next injection in order to eliminate
the high plasma concentrations seen at early times
in the first experiment. Injections of
0.058mmolkg-1 were, therefore, given hourly
between 2h and 16h. It can be seen in Figure 4b
that, in fact, both the plasma and tumour levels of
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30 ugml - from 4h to 16h. In the single dose
comparisons, the CCNU was administered 1 h after
single injections of either 0.3mmolkg1 BENZO
(plasma concentration = 18 igml 1; tumour
concentration = 16Mgml-1) or 1.0mmolkg- of
BENZO (plasma concentration =50 igml-1;
tumour concentration =44 igml - 1). It may be seen
from Figure 4a that the tumour growth delays
produced by CCNU were enhanced equally by the
multiple and single dose BENZO schedules. The
delays caused by 8 and 12mgkg-1 CCNU in
combination with either single or multiple BENZO
were slightly greater than those caused by 12 or
16 mgkg 1 CCNU alone respectively.
Acute lethalityfollowing CCNU
A number of experiments were carried out in which
the LD50/30 (median lethal dose at 30 days) for
CCNU was determined. The results are shown in
Table II. Both experiments with 1902
(2.5mmolkg-1) show considerable enhancement of
CCNU toxicity (DMFs= 1.5 and > 1.4). The
overall DMF for experiments with BENZO
(0.3mmolkg-1) is 1.28.
White cell depression
Two experiments were carried out in which the
effect of 1902 (2.5mmol kg-1) on CCNU induced
depression of peripheral white blood count was
studied. The results of tlle experiments were similar
and have been combined in Figure 5. In each
experiment, 1902 alone depressed the day 3 white
cell count, and the data are therefore shown in two
ways. In Figure 5a the absolute values are shown,
whereas in Figure 5b the counts have been
normalised to 100% in order to remove the initial
effect of the sensitizer alone. It may be seen from
Figure 5b that the response curve to CCNU is
steepened in the presence of 1902 and that the %
counts are significantly lower at 20 and 30mgkg-1
of CCNU. At 40mgkg-1, however, the curves tend
to come together. From the CCNU doses required
to reduce the initial counts to 50% on the basis of
the normalised data, a DMF for 1902 of 1.6 is
obtained.
Three WBC experiments were carried out in
which 0.3mmolkg-1 of BENZO was added to
CCNU. The results have been combined and are
shown in Figure 6. There is again a tendency (not
significant) for BENZO alone to reduce the count.
At 10mgkg-1 of CCNU there is a significant effect
of the sensitizer but no significant difference is seen
at the higher doses. From the CCNU doses
required to reduce the initial normalised counts to
50%, a DMF for BENZO of 1.2 is obtained.
Table II Effect of 1902 and BENZO on LD50/30 for CCNU
Sensitizer LD50130CCNU Dose modifying
anddose (mgkg-1) factor*
Experiment (mmolkg'1) (95% C.L) (95% C.L.)
A 53.5(45.5-63.0) 1.16(0.95-1.41)
BENZO(0.3) 46.3(41.3-52.0)
B - 31.5(21.8-45.3) 1.12(0.62-2.02)
BENZO(0.3) 28.1 (17.8-44.2)
C 49.4(44.4-55.0) 1.19(0.86-1.64)
BENZO(0.3) 41.5(30.7-56.1)
D 54.7(28.6-104.9) 1.74(0.85-3.56)
BENZO(0.3) 31.5(23.3-42.5)
A+B+C+D 47.1(43.4-51.2) 1.28(1.13-1.45)
combined BENZO(0.3) 36.7(33.4-40.3)
E 57.7(48.4-68.7) 1.51(1.01-2.27)
1902(2.5) 38.1 (26.5-57.9)
F >40 >1.4
1902(2.5) 28.9(20.4-40.8)
LD530CCNU alone
*Dose modifying factor= LD- 0/30
LDSO/30CCNU +sensitizer
Values of LD50/30 determined on 6 groups of 4-5 mice in each
experiment receiving graded doses of CCNU and computed using the
GLIM programme for probit analysis. In experiment F, no deaths occurred
in mice receiving CCNU alone at the highest dose administered.
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Figure 6 White cell count in tail vein blood measured
3 days after various doses of CCNU. (@) CCNU
alone; (0) CCNU given 30min after BENZO
(0.3mmolkg-1); The data shown are pooled from 3
separate experiments with a total of 15 mice per
group. Points shown are geometric means +2s.e.
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Figure 5 White cell count in tail vein blood ml
3 days after various doses of CCNU. *,
alone; 0, CCNU given 30min after
(2.5mmolkg-1). In (a) absolute white cell cou
shown. In (b) counts are expressed as a %
control count for CCNU vehicle + 1902. Poi
geometric mean values for groups of 5 mice
bars show +2 s.e.
In one of the three experiments with BENZO,
smears were made of tail vein blood at the same
time as the white cell counts were performed.
Differential counts were carried out on the stained
smears, the cells being classified as mononuclear or
polymorphonuclear. Results are shown in Figure 7.
It is clear from these data that the 2 subpopulations
are about equally sensitive to CCNU, and that any
sensitization by BENZO is minimal for both.
Combination with CTX and MEL
In order to see whether the finding that 1902 and
BENZO cause more tumour sensitization to CCNU
than that brought about by MISO also applies to
other cytotoxic agents, we examined the
combination of these sensitizers with CTX and
MEL. The results of three such experiments are
shown in Tables III and IV. It is clear from Table
40 III that, within the limits of experimental variation,
no enhancement of CTX response is brought about
by either of the lipophilic sensitizers, in contrast to
the small but repeatable effect of MISO. In
easured contrast, however, the response to MEL (Table IV)
1902 is enhanced by 2.5 mmolkg-' 1902 to about the
ints are same extent as by 5mmolkg-t MISO (i.e. DMF
of the 1.5-2.0), with 0.3mmolkg 1 of BENZO being some-
ints are what less effective. The increases in acute MEL
Error toxicity(Table V) brought about by the various sensi-
tizers, however, indicate DMFs similar to those pro-
12p E
E
0
x
8
4
0
uCHEMOSENSITIZATION BY LIPOPHILIC NITROIMIDAZOLES
E 3~~~~~~~~
01
0.3
0 0 10 20 30 40
CCNU dose (mg kg 1)
Figure 7 Differential white cell count in tail vein
blood measured 3 days after various doses of CCNU.
Solid symbols-CCNU alone Open symbols-CCNU
given 30min after BENZO (0.3mmolkg-1). Circles-
mononuclear cells. Triangles-polymorphonuclear
cells.
duced in the tumour. With BENZO there is a
complicating factor in that the toxicity of MEL is
enhanced by the glycol vehicle used for BENZO
administration. The data for white cell count
depression following MEL (Figure 8), however, do
not show any great enhancement by BENZO.
There is, therefore, a different sensitization for the
normal tissue endpoints studied indicating a
necessity for further investigations. It is clear,
however, that these combinations should be used
with caution.
Discussion
In this paper we have confirmed and extended our
previous observation (Workman & Twentyman,
1982) that enhancement of tumour response to
CCNU is greater by lipophilic nitroimidazoles than
by MISO. The two compounds studied further
(1902 and BENZO) have very different shaped
dose-response curves for enhancement (Workman &
Twentyman, 1982), and we have therefore studied
1902 at 2.5mMkg- (equal to the MISO dose used
in many previous studies) and BENZO at the much
lower dose of 0.3mMkg-1. For 1902, the dose
modifying factor (DMF) for tumour response at
low CCNU doses is in excess of 2.5, but this is
accompanied by clear increases in normal tissue
toxicity. The normal tissue endpoint of acute LD50
(DMF=1.5, >1.4) is, of course, obtained at high
doses of CCNU, where the DMF for tumour
response is comparatively reduced and there may
not be any therapeutic gain. The DMF for white
cell count depression, however, (1.6) is obtained at
low doses of CCNU and there appears, therefore,
to be a therapeutic advantage to the combination.
A similar conclusion may also be reached for
BENZO (0.3mMkg-1) where the DMF for tumour
response at low doses of CCNU is 1.5-2.0 and the
DMFs for white cells and for LD50 are 1.2-1.3.
The available data from our own work and from
other workers (Siemann, 1981, 1982; Hirst et al.,
1982) are not sufficiently precise to enable us to
Table III Effect of MISO, 1902 and BENZO on the growth delay induced in the RIF-1
tumour by CTX
CTX Growth delay (days) (2 s.e. limits)
dose Sensitizer
(mgkg1) (mmolkg-1) Expt A Expt B Expt C
0 0.0 0.0 0.0
50 4.6 (3.0- 6.6) 2.8 (1.6- 4.0) 1.3(-0.1- 2.8)
100 12.6(11.0-14.4) 6.9 (6.0- 7.9) 8.4 (6.8-10.1)
150 17.4(15.2-19.9) 15.1(13.4-17.0) 14.9 (11.0-19.7)
50 MISO (5) 5.8 (4.4- 7.4) 3.3 (2.8- 3.8) 6.5 (4.5- 8.8)
100 MISO(5) 13.2(11.0-15.7) 11.3 (9.6-13.3) 15.1 (11.9-18.7)
50 1902 (2.5) 3.6 (2.6- 4.7) 2.6 (2.1- 3.2) 2.4 (1.0- 4.0)
100 1902 (2.5) 9.8 (7.9-12.0) 7.0 (4.9- 9.2) 4.6 (3.0- 6.3)
50 BENZO vehicle 3.8 (2.5- 5.3) 1.5 (1.0- 2.1) 2.8 (1.6- 4.2)
100 BENZO vehicle 5.8 (4.8- 6.9) 6.8 (5.4- 8.3)
50 BENZO (0.3) 5.7 (4.7- 6.8) 3.4 (2.4- 4.6) 4.3 (1.6- 7.9)
100 BENZO (0.3) 14.0(12.4-15.8) 6.3 (5.7- 7.0) 8.1 (5.4-11.3)
BJC-B
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Table IV Effect of MISO, 1902 and BENZO on the growth delay induced in the RIF-l
tumour by MEL
MEL Growth delay (days) (2s.e. limits)
dose Sensitizer
(mgkg-) (mmolkg1) Expt A Expt B Expt C
5 2.8(1.6- 4.2) 4.4(2.8- 6.2) 2.9(1.8- 4.2)
7.5 5.6(4.4- 6.9) 4.0(2.5- 5.7) 5.2(3.4- 7.3)
10 5.9(4.6- 7.4) 5.3(3.9- 6.9)
15 - 10.1(9.1-1 1.1) 11.3(9.8-12.9)
5 MISO (5) 5.7(3.8- 7.8) 7.6(5.4-10.3) 6.4(4.7- 8.3)
7.5 MISO (5) 6.4(4.7- 8.4) 11.1(9.0-13.5) 7.7(6.0- 9.6)
5 1902 (2.5) 8.8(6.6-11.5) 6.9(4.8- 9.4) 4.4(2.7- 6.4)
7.5 1902 (2.5) 10.3(8.4-12.4) 9.6(7.9 -11.5) 9.6(8.3-10.9)
5 BENZO vehicle 5.2(3.5- 7.1) 3.1(1.3- 5.3) 2.1(1.1- 3.2)
7.5 BENZO vehicle 7.8(5.6-10.2) 5.9(4.7- 7.3)
5 BENZO (0.3) 7.3(4.1-11.3) 6.3(4.0- 9.0) 4.3(2.9- 6.0)
7.5 BENZO(0.3) 6.0, 10.5, 13.0* 7.1(5.5- 8.9) 6.3(4.6- 8.3)
*In this first experiment, BENZO was administered in a volume of0.01 mlg- and in this
group, 7/10 mice died; the 3 values given are for the individual survivors. In the other
experiments, BENZO was administered in a volume of 0.005mlg-1.
Table V Effect of MISO, 1902 amd BENZO on LD50/30 for MEL
Sensitizer LD50/30for MEL Dose modifying
and dose (mgkg-1) Factor
Experiment (mmolkg1) (95% C.L.) (95% C.L.)
A 17.6(14.8-20.9)
MISO (5) 9.2 (7.0-12.1) 1.91(1.38-2.64)
1902 (2.5) 9.5 (6.9-13.1) 1.85(1.29-2.66)
BENZO vehicle 11.4 (4.8-27.4) 1.54(0.64-3.73)
BENZO (0.3) 9.5 (6.9-13.1) 1.85(1.35-2.55)
B 22.0(21.1-22.9)
MISO (5) 14.4 (6.9-30.3) 1.53(0.73-3.19)
1902 (2.5) 12.5 (9.4-16.7) 1.76(1.32-2.35)
BENZO vehicle 12.7(10.7-15.1) 1.73(1.45-2.07)
BENZO (0.3) 10.4 (7.9-13.6) 2.12(1.60-2.79)
A+B 19.5(17.6-21.6) -
combined MISO (5) 11.4 (9.8-13.3) 1.71(1.42-2.05)
1902 (2.5) 10.6 (9.5-11.9) 1.84(1.58-2.14)
BENZO vehicle 12.1 (10.9-13.1) 1.61 (1.39-1.86)
BENZO (0.3) 10.0 (9.5-10.5) 1.95(1.74-2.18)
Value ofLD50/30 determined on groups of 4 mice receiving graded doses
of MEL and computed using the GLIM programme for probit analysis.
answer the question "which sensitizer produces the
best therapeutic gain in combination with CCNU?"
(i.e. MISO, 1902 or BENZO). We do not feel,
however, that any one of them is clearly superior or
inferior to the others. What we can say is that these
effects can be produced at very low doses of
BENZO. A similar conclusion has been reached by
Siemann et al. (1983) based on their own data. We
have shown (Workman & Twentyman, 1982) that
enhancement of the response of the KHT tumour is
maintained at BENZO doses down to
0.05mmolkg-1. This is similar to the dose levels
which have been used in the treatment of Chaga's
disease in man (Coura et al., 1978; Raaflub, 1980)CHEMOSENSITIZATION BY LIPOPHILIC NITROIMIDAZOLES 25
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Figure 8 White cell count in tail vein blood measured
3 days after various doses of MEL. (A) Hanks BSS
30min before MEL; (@) BENZO vehicle 30min before
MEL;(O) BENZO(Q.3mmolkg-1) 30minbefore MEL.
and are currently being achieved in a phase 1
clinical study in this unit (Roberts et al.,
unpublished). The balance of evidence from mouse
studies is that enhancement of tumour response to
CCNU is minimal below a MISO dose of
1.25mmolkg-' (Workman & Twentyman, 1982;
Hirst et al., 1982) (although it should be noted that
substantial enhancement at 1.25mmolkg-1 was seen
by Siemann (1981)). This dose produces a peak
plasma concentration in the mouse of 1.25mM
(Workman, 1980). The maximum dose of MISO
which is generally given in the clinic (i.e. 3gm-2),
however, only produces peak plasma levels of 0.5-
0.75mM (Workman, 1980). On this evidence,
therefore, BENZO would appear to be a better
candidate as an enhancer fo CCNU for clinical use.
There is, however, the additional factor that the
elimination half-life of MISO is much longer in
man than in the mouse, and this may, at least in
part, compensate for lower peak levels. A number
of studies have been, or are being, carried out to
determine whether repeated administration of
MISO to mice in order to maintain plasma levels at
around 0.5mM (=l100pgmlP') can produce
chemosensitization. Our own data (Twentyman
& Workman, 1983) indicate minimal
chemosensitization to CCNU, CTX or MEL by a
7h regime of MISO administration, although a set
of results showing greater sensitization has been
reported by Brown and Hirst (1982). Our results of
different time intervals between BENZO and
CCNU reported here are relevant to this question.
Following a dose of 2.5mmolkg-1 BENZO to the
mouse, a plasma concentration of 0.46mM is
maintained between 2h and 8h followed by a fall
to 0.06mM at 16h (Workman et al., in
preparation). At a dose of 0.3mmol kg-1, the peak
of 0.15mM is achieved within 30min, with a
subsequent elimination half life of 2.1h, giving a
concentration of 0.025mM at 8h and undetectable
levels by 24h (i.e. <2x 10-4mM).
Our finding that significant enhancement of
CCNU in the KHT tumour remains at 28h after
0.3mmolkg-1 BENZO indicates that the effect is not
dependent upon the presence of significant
sensitizer plasma levels. On the other hand, the
finding that, for both 0.3 and 2.5mmolkg-' of
BENZO, sensitization is similar for CCNU
administration at 30min and 8h after BENZO
would indicate that length of pre-exposure to a
given plasma level of BENZO is not the critical
factor and our data for the multiple injection
regime with BENZO support this conclusion. We
have recently shown (Workman et al., 1983) that
MISO, 1902 and BENZO all act as inhibitors of
drug metabolism and that these same agents cause
major changes in the pharmacokinetics of CCNU
and its metabolites (Lee & Workman, 1983 and in
preparation). As far as MISO is concerned, the
observed pharmacokinetic changes resulted in
increased peak tumour concentrations of CCNU in
the absence of any increase in peak concentrations
in normal tissues, thus providing a likely basis for
differential chemosensitization of the tumour (Lee
& Workman, 1983 and in preparation). It seems
likely that such pharmacokinetic changes are largely
responsible for the modified tumour and normal
tissue responses which we are now reporting for
BENZO. Sensitization in the absence of detectable
plasma concentrations of BENZO may be due to
the presence of residual bound drug or metabolities
in the liver or elsewhere, and we are currently
carrying out experiments to investigate this.
Our results combining 1902 and BENZO with
CTX indicate that these combinations are
ineffective. The result for CTX+BENZO is in
agreement with the data of McNally (private
communication) for the WHT fibrosarcoma. These
results may indicate that lipophilic sensitizers are
able to interfere with CTX activation by liver
microsomal enzymes as well as with cytotoxic drug
detoxification. Combining the sensitizers with MEL
certainly enhances the tumour response, in
agreement with the observation of Sheldon &
Batten (1982) that BENZO causes considerably
greater enhancement of MEL response than does
MISO in their MT tumour system. The very large
increases in toxicity which we have seen, however,
do not suggest that such combinations are likely to
be of therapeutic value. There is a major problem,
however, in combining BENZO with MEL in that
the glycol vehicle used for BENZO does itself
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enhance MEL (but not CCNU) in both tumour
response (Table IV) and particularly in terms of
LD50/30 (Table V). In these circumstances it is not
possible to determine the extent to which
sensitization to MEL would be brought about by
BENZO in the absence of vehicle effects.
At the present time, it appears to us that the
combination of CCNU with BENZO offers the
most promise of possible clinical benefit based on
current experimental data for chemosensitization by
nitroimidazoles.
The nitroimidazoles used in these studies were kindly
supplied by Dr. C.E. Smithen of Roche (Welwyn). We
thank Jane Donaldson, Kate Smith and Michael Walton
for their technical assistance.
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